RxDoctor Payments Data

Ian Chiu

Family · New York, NYNPI 1477147585

Payments from drug & device makers

$14,202in general payments, 2019–2025

Across 77 payments — averaging $184.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$6K
  • Apellis Pharmaceuticals, Inc.$5K
  • Travere Therapeutics, Inc.$1K
  • Aurinia Pharma U.S., Inc.$377
  • Novartis$239
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$225
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$4,04628%
  • Speaking & faculty fees$4,66533%
  • Travel & lodging$1,89413%
  • Food & beverage$3,58425%
  • Education$140%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,202 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$4,336
Medicare patients
42
Services billed
68

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol99$127,220
VeltassaPatiromer Calcium Sorbitex66$89,378
LokelmaSodium Zirconium Cyclosilicate53$85,270
KerendiaFinerenone30$42,983
AranespDarbepoetin Alfa In Polysorbat32$29,364
JardianceEmpagliflozin24$24,704
Atovaquone11$9,287
ProcritEpoetin Alfa14$6,381
Praluent PenAlirocumab13$6,001
Eplerenone25$5,074
Potassium Citrate ErPotassium Citrate25$4,451
Captopril13$2,183
Guanfacine Hcl47$2,113
Torsemide79$2,078
Febuxostat13$2,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$200$212,490152 claims
BayerKerendia$23$42,98330 claims
AmgenAranesp$6,149$29,36432 claims
Boehringer IngelheimJardiance$203$24,70424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →